Emerald Advisers LLC Decreases Position in Savara Inc. $SVRA

Emerald Advisers LLC decreased its stake in Savara Inc. (NASDAQ:SVRA) by 3.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,371,285 shares of the company’s stock after selling 124,211 shares during the period. Emerald Advisers LLC owned 1.65% of Savara worth $18,407,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after acquiring an additional 3,205 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of Savara during the 1st quarter worth $57,000. Russell Investments Group Ltd. raised its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the last quarter. Xponance LLC purchased a new stake in Savara in the 4th quarter valued at approximately $66,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Savara in the third quarter valued at $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

SVRA opened at $5.74 on Tuesday. The business has a fifty day simple moving average of $5.45 and a 200-day simple moving average of $5.55. The firm has a market cap of $1.18 billion, a PE ratio of -10.25 and a beta of 0.24. Savara Inc. has a fifty-two week low of $2.25 and a fifty-two week high of $7.01. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities analysts predict that Savara Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

SVRA has been the subject of several recent analyst reports. William Blair set a $10.00 target price on shares of Savara in a research note on Monday, March 16th. Oppenheimer assumed coverage on shares of Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday, March 16th. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.